Compstatin Peptide Analogs for Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors of complement activation, such as soluble complement receptor 1 and humanized monoclonal anti-C5 antibodies, are large molecular weight proteins that are difficult to manufacture and deliver, and there is a need for smaller, more stable, and less costly agents to inhibit complement activation effectively.
Innovation Solution
Development of analogs and mimetics of the peptide Compstatin, with modified sequences such as Xaa1-Cys-Val-Xaa2-Gln-Asp-Trp-Gly-Xaa3-His-Arg-Cys-Xaa4, where Xaa1, Xaa2, Xaa3, and Xaa4 are specific amino acids or their analogs, and the two Cys residues are joined by a disulfide bond, to enhance complement-inhibiting activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If large molecular weight proteins (soluble complement receptor 1, anti-C5 antibodies) are used to inhibit complement activation, then complement inhibition activity is achieved, but manufacturing difficulty and delivery complexity increase
Solution Approach 1:
The patent segments the large molecular weight complement inhibition function into smaller peptide units. Specifically, it identifies and isolates the critical 13-residue cyclic segment (Compstatin) from larger proteins, creating a truncated version that retains complete complement inhibitory activity while being much smaller and easier to manufacture.
Solution Approach 2:
The patent extracts the essential functional domain from large complement-regulating proteins. By using phage-displayed combinatorial random peptide libraries, it identifies and extracts the minimal peptide sequence (ICVVQDWGHHRCT) that contains the complete complement inhibition activity, separating this small active fragment from the large parent proteins.
2Reliability
If large molecular weight proteins are used as complement inhibitors, then complement activation is suppressed, but delivery and administration complexity increase
Solution Approach 1:
The patent divides the large protein molecules into smaller peptide segments that can be more easily delivered and administered. The 13-residue Compstatin peptide is significantly smaller than soluble complement receptor 1 (240 kDa) or anti-C5 antibodies (26,000 kDa), enabling simpler delivery methods and reduced administration complexity.
3Object-affected harmful factors
If conventional complement inhibitors are used, then complement-mediated tissue injury is reduced, but production cost increases
Solution Approach 1:
The patent replaces expensive, complex large protein molecules with cheaper, smaller peptide molecules. The simplified peptide structure of Compstatin (13 residues compared to hundreds in parent proteins) enables more economical synthesis and production, reducing manufacturing costs while maintaining therapeutic effectiveness against complement-mediated tissue injury.
Solution Approach 2:
The patent extracts only the essential functional portion of expensive parent proteins, creating a minimal peptide version that retains complete activity. This extraction of the critical 13-residue sequence from much larger, more expensive proteins dramatically reduces production costs while preserving the ability to prevent complement-mediated tissue damage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Compstatin analogs demonstrate significantly improved complement-inhibiting activity, with some exhibiting 5-fold to 80-fold greater activity than Compstatin, making them more effective and practical for clinical use.
Implementation Method 1
the two Cys residues are joined by a disulfide bond
Data Source
AI summary
Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed.